Cardiol Therapeutics files Q3 2026 MD&A, citing need for more financing as it develops heart inflammation drugs
Cardiol Therapeutics, a Canadian company developing treatments for inflammation and fibrosis in heart disease such as recurrent pericarditis, acute myocarditis and heart failure, issued its MD&A for the three and nine months ended September 30, 2026, dated November 12, 2026. The excerpt contains only the introduction and forward-looking statements and risk factors, including negative operating cash flow, a history of losses and a requirement for additional financing. It gives no financial results or clinical or regulatory updates.
Company's press release (SEC filing): Cardiol Therapeutics Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release